Business
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Topline data expected in second half of 2025 to support potential sNDA submission for label expansion of IGALMI® in the home setting Company has $35M of cash following closing of recent equity financing NEW HAVEN, Conn., March 11, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that, following the successful raise of $14 million gross proceeds in
About this update from Bioxcel Therapeutics, Inc.
[{"type":"image","alt":"BioXcel Therapeutics","displaySize":"","headline":null,"caption":"BioXcel Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":220,"height":123,"url":"https://media.zenfs.com/en/globenewswire.com/184443491f4795fadfc360af09172b87"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Ugin_5Up8vRFuzpQTrOKug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/184443491f4795fadfc360af09172b87","width":220,"height":123}},"lazy":false},{"type":"text","content":"Topline data expected in second half of 2025 to support potential sNDA submission for label expansion of IGALMI® in the home setting","length":137,"tagName":"p"},{"type":"text","content":"Company has $35M of cash following closing of recent equity financing ","length":69,"tagName":"p"},{"type":"text","content":"NEW HAVEN, Conn., March 11, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that, following the successful raise of $14 million gross proceeds in an equity financing that closed on March 4, 2025, it has approximately $35 million in cash. The strengthened cash position will support continued advancement of the Company’s pivotal Phase 3 SERENITY At-Home trial. The trial is designed to evaluate the safety of BXCL501, BioXcel Therapeutics’ investigational, proprietary, orally dissolving film formulation of dexmedetomidine, in the at-home setting for the acute treatment of agitation associated with bipolar disorders or schizophrenia.","length":797,"tagName":"p"},{"type":"text","content":"“We are pleased the recent financing enables us to progress our SERENITY At-Home trial,” said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. “Patient enrollment is continuing and topline data results expected in the second half of 2025 are intended to support a potential sNDA submission to expand the label for IGALMI® in the at-home setting. We are highly motivated by the prospect of bringing — for the first time — an acute treatment option for agitation to millions of additional patients in this setting.”","length":513,"tagName":"p"},{"type":"text","content":"About the SERENITY At-Home Phase 3 Trial","length":40,"tagName":"p"},{"type":"text","content":"The...